e-Drug3D

1909

REVEFENACIN

INN
REVEFENACIN

cas 864750-70-9

CLASS

RESPIRATORY
TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
ANTICHOLINERGIC
MUSCARINIC ANTAGONIST LEADING TO BRONCHODILATION

ROUTE (list)

INHALATION

ATC code

R03BB08

PK parameters

F 3 PERCENT (INHALATION COMPARED TO ORAL)
Tmax 0.45 HOUR
VD 218 LITER
PPB 71 PERCENT
t1/2 46 HOUR

Solubility

SLIGHTLY SOLUBLE IN WATER

Target

TARGET MUSCARINIC RECEPTORS M1 TO M5

DrugCentral

Muscarinic acetylcholine receptor M1 UNIPROT P11229 CHRM1

Muscarinic acetylcholine receptor M2 UNIPROT P08172 CHRM2

Download SDF file

Carbamic acid, N-[1,1'-biphenyl]-2-yl-, 1-[2-[[4-[[4-(aminocarbonyl)-1-piperidinyl]methyl]benzoyl]methylamino]ethyl]-4-piperidinyl ester

Formula:
C35H43N5O4

Calculated chemical properties:

MW 597.74
NB_atoms 44
XLogP 4.84
PSA 105.065
NB_HD 3
NB_HA 9
fsp3 0.40
Lipinski(0=no;1=yes) 0

FDA
NDA 210598 (pdf not found) INN (REVEFENACIN) YUPELRI (MYLAN IRELAND LTD) APPROVAL= AP YEAR= 2018 NEWMOLECULARENTITY
NDA 218089 (pdf not found) INN (REVEFENACIN) REVEFENACIN (MANKIND PHARMA LTD) APPROVAL= TA YEAR= 2025